BioCentury | Jan 12, 2019
Finance

We all fall down

...platinum-sensitive, relapsed ovarian cancer Theravance Biopharma Inc. (NASDAQ:TBPH) / Mylan N.V. (NASDAQ:MYL) FDA approves Yupelri revefenacin...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Nov 16, 2018
Clinical News

Theravance secures U.S. approval for Yupelri in COPD

...Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a...
...the wholesale acquisition cost (WAC). Theravance is partnered with Mylan to develop and commercialize nebulized revefenacin...
...Francisco, Calif. Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Product: Yupelri revefenacin Business: Pulmonary Jennie Walters Yupelri, revefenacin (TD-4208, gsk1160724) Mylan...
BioCentury | Nov 9, 2018
Company News

Theravance secures U.S. approval for Yupelri in COPD

...Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a...
...the wholesale acquisition cost (WAC). Theravance is partnered with Mylan to develop and commercialize nebulized revefenacin...
...Theravance gained $1.26 to $25.81 Friday, while Mylan lost $0.20 to $36.95. Jennie Walters Yupelri, revefenacin (TD-4208, gsk1160724) Mylan...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...an intact uterus PDUFA date 10/28/18 Theravance Biopharma Inc. (NASDAQ:TBPH) / Mylan N.V. (NASDAQ:MYL) Revefenacin (TD-4208...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...an intact uterus PDUFA date 10/28/18 Theravance Biopharma Inc. (NASDAQ:TBPH) / Mylan N.V. (NASDAQ:MYL) Revefenacin (TD-4208...
BioCentury | Feb 2, 2018
Product Development

Local advantage

...in localized therapies began with the development of revefenacin (TD-4208) for chronic obstructive pulmonary disease. Revefenacin...
...minimize systemic side effects associated with other LAMAs, such as dry mouth and constipation. As revefenacin...
...in was our ability to discover medicines for the lung, with the most recent being revefenacin...
BioCentury | Feb 2, 2018
Clinical News

FDA accepts NDA from Therevance and Mylan for COPD candidate revefenacin

...NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA accepted for review an NDA for revefenacin (TD-4208...
...In 2016, the companies reported data from a pair of Phase III trials showing that revefenacin...
...San Francisco, Calif. Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Product: Revefenacin (TD-4208) Business: Pulmonary Elizabeth S. Eaton muscarinic agonist revefenacin TD-4208 Mylan...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...GvHD) Ph III data 4Q17 Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL) / Theravance Biopharma Inc. (NASDAQ:TBPH) Revefenacin...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...panel; BsUFA date 7/13/17; 9/3/17 Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL) / Theravance Biopharma Inc. (NASDAQ:TBPH) Revefenacin...
Items per page:
1 - 10 of 38